206 related articles for article (PubMed ID: 34995329)
1. Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer.
Mori T; Tanaka H; Deguchi S; Yamakoshi Y; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Ohira M
PLoS One; 2022; 17(1):e0262455. PubMed ID: 34995329
[TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab.
Ishido K; Tanabe S; Katada C; Ishibashi Y; Kitahara G; Onoue M; Kubota Y; Furue Y; Wada T; Watanabe A; Kusano C
J Gastrointest Cancer; 2023 Jun; 54(2):485-491. PubMed ID: 35437632
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
5. Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases.
Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Takamura H; Ueda N; Kosaka T
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2955-2960. PubMed ID: 33112554
[TBL] [Abstract][Full Text] [Related]
6. Tertiary lymphoid structures and gastric cancer prognosis.
Kemi N; Ylitalo O; Väyrynen JP; Helminen O; Junttila A; Mrena J; Böhm J; Kauppila JH
APMIS; 2023 Jan; 131(1):19-25. PubMed ID: 36205614
[TBL] [Abstract][Full Text] [Related]
7. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.
Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H
Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777
[TBL] [Abstract][Full Text] [Related]
8. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
Front Immunol; 2021; 12():793964. PubMed ID: 34987518
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
[TBL] [Abstract][Full Text] [Related]
10. DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer.
Sunakawa Y; Inoue E; Matoba R; Kawakami H; Sato Y; Nakajima TE; Muro K; Ichikawa W; Fujii M
Future Oncol; 2019 Jul; 15(21):2441-2447. PubMed ID: 31140303
[No Abstract] [Full Text] [Related]
11. Comprehensive analysis of tertiary lymphoid structures-related genes for prognostic prediction, molecular subtypes and immune infiltration in gastric cancer.
Zhou Q; Lan L; Wang W; Xu X; Wang W
Aging (Albany NY); 2023 Nov; 15(22):13368-13383. PubMed ID: 38015717
[TBL] [Abstract][Full Text] [Related]
12. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
13. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
Sano A; Sohda M; Nakazawa N; Ubukata Y; Kuriyama K; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sakai M; Ogawa H; Shirabe K; Saeki H
BMC Cancer; 2022 Jan; 22(1):22. PubMed ID: 34980017
[TBL] [Abstract][Full Text] [Related]
14. [Experience with Nivolumab in the Treatment of Metastatic Gastric Cancer].
Takao C; Matsuhashi N; Murase Y; Yasufuku I; Tanahashi T; Yamaguchi K; Matsui S; Imai H; Tanaka Y; Takahashi T; Yoshida K
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1546-1548. PubMed ID: 30382073
[TBL] [Abstract][Full Text] [Related]
15. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma.
Li H; Wang J; Liu H; Lan T; Xu L; Wang G; Yuan K; Wu H
Aging (Albany NY); 2020 Feb; 12(4):3451-3472. PubMed ID: 32087064
[TBL] [Abstract][Full Text] [Related]
16. Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report.
Takami T; Yasuda K; Uozumi N; Musiake Y; Shintani H; Kataoka N; Yamaguchi T; Makimoto S
J Med Case Rep; 2021 Dec; 15(1):604. PubMed ID: 34930435
[TBL] [Abstract][Full Text] [Related]
17. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Yamamoto K; Makino T; Takahashi T; Kawashima A; Haruna M; Hirata M; Ueyama A; Iwahori K; Satoh T; Kurokawa Y; Eguchi H; Doki Y; Wada H
Cancer Immunol Immunother; 2023 Jan; 72(1):169-181. PubMed ID: 35776160
[TBL] [Abstract][Full Text] [Related]
18. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
[TBL] [Abstract][Full Text] [Related]
19. Alterations in Intratumoral Immune Response before and during Early-On Nivolumab Treatment for Unresectable Advanced or Recurrent Gastric Cancer.
Sato Y; Yamashita H; Kobayashi Y; Nagaoka K; Hisayoshi T; Kawahara T; Kuroda A; Saito N; Iwata R; Okumura Y; Yagi K; Aiko S; Nomura S; Kakimi K; Seto Y
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068925
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Machine Learning Model for Detection and Classification of Tertiary Lymphoid Structures in Gastrointestinal Cancers.
Li Z; Jiang Y; Li B; Han Z; Shen J; Xia Y; Li R
JAMA Netw Open; 2023 Jan; 6(1):e2252553. PubMed ID: 36692877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
